Skip to content
Disclosery

Athyrium Capital Management, LP

Follow

13F filer, CIK 1728001, New York, NY

Athyrium Capital Management, LP reported $154,146,384 across 7 holdings for the quarter ended 2023-06-30, in a 13F-HR filed 2023-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-23-000094

Period
2023-06-30
Reported value
$154M
Holdings
7
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AMRYT PHARMA LTD - SPNR ADRexited-8,857,268-$129M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2023

Share positions as resolved from 13F-HR 0001123292-23-000094, largest first. % of portfolio is the value over $154,146,384, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RVLPQRVL PHARMACEUTICALS PLC ORDINAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 14,600,444 shares; 2023Q1: 14,600,444 shares; 2023Q2: 14,600,444 shares 14,600,444$8.18M5.31%0Timeline
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 1,694,481 shares; 2023Q2: 1,694,481 shares 1,694,481$6.52M4.23%0
PBYIPUMA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 1,792,114 shares; 2023Q1: 1,792,114 shares; 2023Q2: 1,792,114 shares 1,792,114$6.33M4.1%0Timeline

Principal amounts

Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).

SecurityTypeAmountValueChange
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INC NOTE 7.250%12/0principal103,500,000$60.5M0
OMEROS CORPOMEROS CORP NOTE 5.250% 2/1principal71,979,000$52.8M+6,843,000
Omeros CorpOmeros Corp NOTE 6.250%11/1principal11,005,000$11M0
PARATEK PHARMACEUTICALS INCPARATEK PHARMACEUTICALS INC Convertible Bondprincipal9,000,000$8.85M0

Sold out in Q2 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
AMRYT PHARMA LTD - SPNR ADRAMRYT PHARMA LTD - SPNR ADR8,857,268$129Mshares

How Q2 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-23-000094 base2023-08-14acceptance time not in the bulk data set